DYNE THERAPEUTICS INC's ticker is DYN and the CUSIP is 26818M108. A total of 95 filers reported holding DYNE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27,359,414 | -10.4% | 3,053,506 | +12.5% | 0.01% | 0.0% |
| Q2 2023 | $30,530,284 | -12.9% | 2,713,803 | -10.8% | 0.01% | -25.0% |
| Q1 2023 | $35,063,424 | +1.3% | 3,043,700 | +2.0% | 0.01% | 0.0% |
| Q4 2022 | $34,601,702 | -7.9% | 2,985,479 | +0.9% | 0.01% | 0.0% |
| Q3 2022 | $37,583,000 | +87.0% | 2,959,272 | +1.1% | 0.01% | +60.0% |
| Q2 2022 | $20,099,000 | -29.6% | 2,925,714 | -1.2% | 0.01% | -16.7% |
| Q1 2022 | $28,557,000 | -16.1% | 2,962,333 | +3.4% | 0.01% | -14.3% |
| Q4 2021 | $34,055,000 | -27.0% | 2,864,200 | -0.3% | 0.01% | -30.0% |
| Q3 2021 | $46,669,000 | -23.9% | 2,873,677 | -1.5% | 0.01% | -28.6% |
| Q2 2021 | $61,363,000 | +27.6% | 2,916,514 | -5.8% | 0.01% | +16.7% |
| Q1 2021 | $48,075,000 | -27.7% | 3,095,580 | -2.2% | 0.01% | -29.4% |
| Q4 2020 | $66,450,000 | +10.9% | 3,164,320 | +6.6% | 0.02% | 0.0% |
| Q3 2020 | $59,932,000 | – | 2,968,393 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vida Ventures Advisors, LLC | 2,220,034 | $25,730,194 | 34.58% |
| MPM ASSET MANAGEMENT LLC | 4,951,303 | $57,385,602 | 24.01% |
| Atlas Venture Life Science Advisors, LLC | 9,869,483 | $114,387,308 | 13.78% |
| Logos Global Management LP | 2,150,000 | $24,918,500 | 2.92% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 641,068 | $7,417,157 | 2.29% |
| Deep Track Capital, LP | 2,684,200 | $31,109,878 | 1.31% |
| EcoR1 Capital, LLC | 2,322,384 | $26,916,431 | 0.82% |
| Vivo Capital, LLC | 577,642 | $6,695 | 0.77% |
| HighVista Strategies LLC | 102,431 | $1,187,175 | 0.70% |
| Monashee Investment Management LLC | 123,719 | $1,433,903 | 0.62% |